• General Dermatology
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management

Arcutis Finalizes Enrollment in Pivotal Phase 3 Trial of Roflumilast Cream for AD


INTEGUMENT-1 and 2 trial data for atopic dermatitis are expected at the end of 2022.

Arcutis Biotherapeutics, a biopharmaceutical company that develops therapies in immuno-dermatology, has completed the enrollment of participants in its INTEGUMENT-2 pivotal phase 3 trial of roflumilast cream 0.15%.1 If data from both trials are successful, the trials will provide a sufficient basis to submit a supplemental New Drug Application (sNDA) in 2023 for the treatment of mild-to-moderate atopic dermatitis (AD) in patients aged 6 years and older.

INTEGUMENT-2 includes 683 adults and children with AD. INTEGUMENT-1 enrollment was finalized in early August 2022 and was an identically designed pivotal phase 3 trial. After completing both clinical trials, participants will be eligible to enroll in an open-label extension study (INTEGUMENT-OLE) which evaluates AD treatment with once-daily roflumilast cream 0.15% for up to 12 months.

The “Interventional Trial Evaluating Roflumilast Cream for the Treatment of Atopic Dermatitis” 2 (INTEGUMENT-2) is a phase 3, parallel group, double blind, vehicle-controlled trial designed to monitor the safety and efficacy of roflumilast cream 0.15% or vehicle applied once daily for 4 weeks to participants 6 years of age and older with mild-to-moderate AD. Roflumilast cream 0.15% is a topical formulation of roflumilast applied once a day, and a highly potent and selective phosphodiesterase type 4 inhibitor (PDE4).

According to Arcutis, “The primary endpoint is Investigator Global Assessment (IGA) Success, defined as a Validated Investigator Global Assessment – Atopic Dermatitis (vIGA- AD) score of ‘clear’ or ‘almost clear’ plus a 2-grade improvement from baseline at week 4. Multiple secondary endpoints will also be evaluated, including itch as measured by the Worst Itch-Numerical Rating Scale (WI-NRS) as well as the proportion of subjects who attain at least a 75% reduction in the Eczema Area and Severity Index (EASI-75) at week 4.”

AD affects more than 9.6 million children and 16.5 million adults in the US as the most common type of eczema.2 As a chronic condition, it can flare up at any time and even overlap with other types of eczema. AD typically appears during childhood, as early as 6 months old. In some patients, symptoms may reduce over time, while others will experience severe flare ups into adulthood.


  1. Arcutis completes enrollment in integument-2 pivotal phase 3 trial of roflumilast cream in atopic dermatitis. Arcutis Biotherapeutics. Published August 23, 2022. Accessed August 24, 2022. https://www.arcutis.com/arcutis-completes-enrollment-in-integument-2-pivotal-phase-3-trial-of-roflumilast-cream-in-atopic-dermatitis/
  2. What is atopic dermatitis and how can I tell if I have it? National Eczema Association. Accessed August 24, 2022. https://nationaleczema.org/eczema/types-of-eczema/atopic-dermatitis/
Related Videos
Lawrence Eichenfield, MD, an expert on atopic dermatitis
Elizabeth Kiracofe, MD, FAAD, and Jenny Murase, MD, experts on atopic dermatitis
Elizabeth Kiracofe, MD, FAAD, and Jenny Murase, MD, experts on atopic dermatitis
Video 2 - "Optimizing Long-Term Care: Physician Insights on Secondary Dermatitis Management" - 2 KOLs in this video.
Video 2 - "Real-World Clinical Experience With Ruxolitinib Cream Monotherapy to Manage Atopic Dermatitis"
Video 1 - "Creating a Connection: First Appointment Insights and Critical Inquiries Providers Should Make"
Video 1 - "Insights for Clinicians: Leveraging Real-World Data for Informed Practice"
Video 2 - "Atopic Dermatitis and Contact Dermatitis: Navigating Intersecting Pathways and Optimal Management Strategies"
Video 1 - "Decoding Atypical Atopic Dermatitis: Unraveling Complex Cases and Advanced Diagnostic Strategies"
© 2024 MJH Life Sciences

All rights reserved.